Quick Answer
Cell Source, Inc. reported Cash and Equivalents of $222.7 thousand for fiscal year 2022.
Cell Source, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $222.7K | +139.2% |
| 2021 | $93.1K | -61.5% |
| 2020 | $241.6K | +765.8% |
| 2019 | $27.9K | +47.4% |
| 2018 | $18.9K | -94.9% |
| 2017 | $371.0K | +9834.4% |
| 2016 | $3.7K | -46.2% |
| 2015 | $6.9K | -64.4% |
| 2014 | $19.5K | -32.5% |
| 2013 | $28.9K | -82.1% |
| 2012 | $161.3K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2023 | $22.0K | +746.9% | -83.5% |
| March 31, 2023 | $133.0K | +0.8% | -40.3% |
| December 31, 2022 | $222.7K | +139.2% | +237.7% |
| September 30, 2022 | $65.9K | -89.0% | +2439.1% |
| June 30, 2022 | $2.6K | -96.8% | -98.0% |
| March 31, 2022 | $132.0K | — | +41.8% |
| December 31, 2021 | $93.1K | -61.5% | -84.5% |
| September 30, 2021 | $599.5K | +995.2% | +633.7% |
- Cell Source, Inc. showed an increase of +139.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2022 period, Cell Source, Inc.’s cash and equivalents has grown by 38.0% (from $161.3 thousand to $222.7 thousand).
- The most recent figure is from Cell Source, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on August 8, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: